Gastro Education 2018
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Page 48
September 06-07, 2018
London, UK
14
th
International Conference on
Gastro Education
A
lthough cisplatin is a widely used anticancer drug for the
treatment of a variety of tumors, its use is critically limited
because of adverse effects such as ototoxicity, nephrotoxicity,
neuropathy, and gastro-intestinal damage. Cisplatin treatment
increases oxidative stress biomarkers in the small intestine,
which may induce apoptosis of epithelial cells and thereby elicit
damage to the small intestine. Nicotinamide adenine dinucleotide
(NAD+) is a cofactor for various enzymes associated with cellular
homeostasis. In the present study, we demonstrated that the
hyper-activation of poly(ADP-ribose) polymerase-1 (PARP-1) is
closelyassociatedwith thedepletionofNAD+ in thesmall intestine
after cisplatin treatment, which results in down regulation of
sirtuin1 (SIRT1) activity. Furthermore, a decrease in SIRT1 activity
was found to play an important role in cisplatin-mediated small
intestinal damage through nuclear factor (NF)-κBp65 activation,
facilitated by its acetylation increase. However, use of dunnione
as a strong substrate for the NADH:quinone oxidoreductase 1
(NQO1) enzyme led to an increase in intracellular NAD+ levels
and prevented the cisplatin-induced small intestinal damage
correlating with the modulation of PARP-1, SIRT1, and NF-κB.
These results suggest that direct modulation of cellular NAD+
levels by pharmacological NQO1 substrates could be a promising
therapeutic approach for protecting against cisplatin-induced
small intestinal damage.
sweetarpana123@gmail.comDunnione ameliorates cisplatin-induced small intestinal
damage by modulating NAD+ metabolism
Arpana Pandit
Wonkwang University, Republic of South Korea
J Clin Gastroenterol Hepatol 2018, Volume 2
DOI: 10.21767/2575-7733-C2-006




